Evidence map›Paper›PMID 37747661›Full record

ArticleNeurology and therapy2023

Experience of Daily Life with Generalized Myasthenia Gravis: A Qualitative Investigation and Assessment of Instrument Content Validity.

Christopher A Hartford, Steven A Sherman, Stella Karantzoulis, Isabelle Guillemin, Michael G Phinney, Kimberly L Kelly, Kayla E Negron, Shruti M Raja, Diana Rofail

Open access · goldAbstract read
In one paragraph

Article in Neurology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Christopher A HartfordRegeneron Pharmaceuticals, Inc., 1 Rockwood Rd, Sleepy Hollow, NY, 10591, USA. christopher.hartford@regeneron.com.ORCID http://orcid.org/0000-0001-7095-0106
Steven A ShermanRegeneron Pharmaceuticals, Inc., 1 Rockwood Rd, Sleepy Hollow, NY, 10591, USA.
Stella KarantzoulisIQVIA, Durham, NC, USA.
Isabelle GuilleminIQVIA, Lyon, France.
Michael G PhinneyIQVIA, Durham, NC, USA.
Kimberly L KellyIQVIA, Durham, NC, USA.
Kayla E NegronIQVIA, Durham, NC, USA.
Shruti M RajaDuke University Medical Center, Durham, NC, USA.
Diana RofailRegeneron Pharmaceuticals, Inc., 1 Rockwood Rd, Sleepy Hollow, NY, 10591, USA.
IQVIA (United States) · USRegeneron (United States) · USDuke Medical Center · USIQVIA (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGeneralized myasthenia gravis (gMG) is a rare autoimmune disease. Symptoms of gMG are diverse, and understanding of their impact on patients is limited. This qualitative study aimed to provide an in-depth exploration of patients' daily experiences of gMG.

methodsPublished qualitative studies were reviewed to identify the most important signs, symptoms, and functional impacts related to the patient experience in gMG. Semi-structured hybrid concept elicitation interviews (allowing spontaneous generation of disease concepts) and cognitive debriefing interviews (assessing the validity of existing disease assessments) were conducted with clinicians and adult patients with gMG. Signs, symptoms, and impacts were reviewed to understand which were most salient (i.e., reported by at least 50% of patients, with disturbance rating 5 or higher [10-point numeric scale]); concept saturation was also assessed. The disease conceptual model was updated. Existing clinical outcomes assessments (COAs) that capture how patients feel, function, and survive were assessed.

resultsInterviews with patients (n = 24) identified seven new signs and symptoms and 37 new impacts compared with the literature. Concept saturation was reached. Signs and symptoms identified by patients as most important (salient) were shortness of breath, general fatigue, muscle weakness of arms, legs, and neck, dysphonia, dysarthria, trouble swallowing liquids, choking, and heat sensitivity. Patient-identified salient impacts were work life, depression, difficulty walking, grooming hair, showering, and brushing teeth, eating, personal relationships, family life, and participating in social activities. Clinicians considered ocular, respiratory, swallowing, speech/talking, and extremity function as key clinical manifestations of gMG. Patients and clinicians found clinical outcome assessments (COAs) to be conceptually relevant and comprehensive.

conclusionThis research provides a holistic understanding of gMG signs, symptoms, and impacts experienced by patients, as observed by patients and clinicians. The conceptual model of gMG highlights the range of signs, symptoms, and impacts that adult patients with gMG experience in their everyday lives, emphasizing the humanistic impact and unmet needs.

Indexed as

Clinical outcome assessmentsDisease modelImpactsMyasthenia gravisPatient experienceSignsSymptoms

Identifiers

PMID37747661
PMCPMC10630275
OpenAlexW4387002060

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.